CapVest and Parquest Agree Terms on IPN’s Acquisition of Sopral
Inspired Pet Nutrition (“IPN”), the fast-growing pet food company controlled by CapVest Partners LLP (“CapVest”), and Parquest, a leading investment firm, have agreed terms on the acquisition of Sopral, a prominent branded pet food platform serving the European market, with manufacturing operations based in France.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708134461/en/
Sopral products
The transaction is subject to customary regulatory approvals and closing conditions. Financial terms have not been disclosed.
Based in Pléchâtel, Brittany, France, Sopral is a leading manufacturer of branded premium dry petfood with a comprehensive range of high-quality nutritional solutions, including Pro-Nutrition Prestige, Pure Life and Protect brands. Sopral has a strong footprint and reputation in France and a fast growing online and international market presence in over 50 countries around the world. Employing over 130 people, the company operates a state-of-the-art manufacturing facility totalling 13,400 square metres and is known for its advanced in-house R&D capabilities.
Arthur van Benthem, CEO of IPN, said: “Sopral is an excellent and growing business, with a great team, leading brands and outstanding capabilities as a manufacturer of superior-quality pet food. This highly complementary strategic combination marks a significant milestone for IPN and provides us with a state-of-the-art manufacturing, logistics and sales platform to grow and realise our ambitious growth plans in the European market. We look forward to working with the Sopral team to build on their significant successes to date.”
Matthew Fargie of CapVest, said: “Following on from the acquisition of Butcher’s last year, Sopral is another great addition to the IPN platform, creating significant capability and scale to underpin IPN’s growth in Europe. The acquisition will unlock a number of new opportunities for organic and acquisition-lead growth and is a great example of CapVest’s passion for building strong, differentiated global companies through significant investment in people, technology, innovation, and capabilities.”
Thomas Babinet, Partner at Parquest, said: “When we invested in Sopral in 2018, our ambition was to unlock the company’s full potential together with the management team led by Yannick Guého. Collectively, we have transformed a quality-focused manufacturer into a premium brand, firmly positioned in high-growth markets. We revamped the flagship brands, strengthened the distribution network, launched an e-commerce platform, and doubled production capacity. We would like to warmly thank Yannick and his team for their unwavering commitment throughout this journey.”
Headquartered in Thirsk, North Yorkshire, UK, IPN is best known as the UK dog food market leader with its high-quality natural dog meals and pet treats under the “Harringtons”, “Butcher’s” and “Wagg” brands. With a strong commitment to natural, high-quality ingredients, IPN is dedicated to providing affordable nutritious pet food that supports the health and well-being of pets. The firm was acquired by international investment firm and buy-and-build specialist CapVest in 2020 and subsequently acquired Pet Food UK in 2021 along with its high quality and distinctively branded premium dog and cat pet food brands “Aatu”, “Barking Heads” and “Meowing Heads”. In August 2024, IPN acquired Butcher’s Pet Care (“BPC”), the UK’s leading wet pet food manufacturer.
About CapVest
CapVest is a leading international private equity investor that partners with ambitious companies supplying essential goods and services to transform their businesses. As an active and patient investor, CapVest has established a strong record of success in delivering attractive returns by working closely with management in transforming the size and scale of its portfolio companies through a combination of organic and acquisition led growth.
CapVest seeks to invest in highly resilient industries where the demand driver for the product or service is non-discretionary. Its core sectors include consumer staples, healthcare and essential services.
IPN were advised by Natixis Partners and Spayne Lindsay.
About Parquest
Founded in 2002, Parquest is a recognised private equity player in France. Parquest supports SMEs and their management teams in implementing ambitious development projects in France and abroad. For over 20 years, Parquest has contributed to the development of market-leading companies by supporting them over the long term.
Parquest was advised by Amala Partners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250708134461/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boyd Unveils a High-Capacity Coolant Distribution Unit with a 2.3 Megawatt Capacity for AI Liquid Cooling Applications8.7.2025 14:05:00 CEST | Press release
Boyd’s ROL2300 Coolant Distribution Unit Efficiently and Reliably Cools Modern High Power AI Processors in Hyperscaler, Colocation, and Enterprise Data Centers Today, Boyd announces a significant expansion of its liquid cooling product portfolio with a new high-capacity coolant distribution unit (CDU). Boyd’s new ROL2300 is a liquid-to-liquid in row system that enables high performance cooling for modern AI processor applications and is immediately available to purchase in volume. To learn more about the ROL2300, watch the video here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708530818/en/ Boyd's high capacity ROL2300 in row coolant distribution unit (CDU) efficiently and reliably cools modern high power AI processors in hyperscale, colocation, and enterprise data centers with up to a 2.3 megawatt capacity. A single ROL2300 can efficiently cool over 10 NVL72 racks. It is optimized to easily fit in data center server
Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD8.7.2025 14:00:00 CEST | Press release
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announce today that the China National Medical Products Administration (NMPA) has approved Heng Qin® (Perfluorohexyloctane Eye Drops) for the treatment of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708514269/en/ Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months. According to the Chinese Expert Consensus on M
Esri Launches New E-Commerce Experience for Demographic Data8.7.2025 14:00:00 CEST | Press release
Organizations Can Purchase Updated, Authoritative Datasets Ranging from Census to Retail Demand To further provide individuals and organizations with the authoritative demographic data they need, Esri, the global leader in geographic information system (GIS) technology, has launched a new e-commerce experience for data in the Esri Store. A one-stop shop for enhanced, reliable information relating to people and geography, Esri’s location data store is designed to make these resources more accessible for users that rely on spatial data. “We are thrilled to launch our new e-commerce experience, making it easier than ever for customers to access the data they need to make better decisions,” said Rob Elkins, Esri director of product management. “Organizations will have access to current-year and five-year estimates for more than 2,000 demographic and socioeconomic characteristics in the US, as well as census and American Community Survey (ACS) information, consumer spending trends, market p
Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella8.7.2025 14:00:00 CEST | Press release
Researchers aim to discover dominant subtypes of plasmablasts initiating from the MMR vaccine in order to develop neutralizing antibody candidate therapies The Vanderbilt University Medical Center and Parse Biosciences today announced a strategic collaboration to generate a single cell atlas focused on understanding the diversity of plasmablasts – early immune cell clonotypes critical in the formation of neutralizing antibodies – for measles, mumps and rubella. This effort aims to build the most comprehensive understanding of the formation of neutralizing antibodies to the vaccine and to identify the dominant and effective antibodies to these infectious agents. Dr. James Crowe, Director of Vanderbilt's Center for Antibody Therapeutics, will lead the development of the large-scale immune cell study. “This collaboration enables us to create the largest single cell atlas of neutralizing plasmablasts ever assembled,” states Crowe. “By sequencing and mapping tens of millions of B cell recep
ViaLase Announces Strategic Leadership Transitions to Support Commercial Growth8.7.2025 14:00:00 CEST | Press release
ViaLase, Inc., a medical technology company pioneering noninvasive femtosecond laser treatments for glaucoma, today announced key changes to its executive leadership team as the company prepares for commercial launch and regulatory approvals in both the United States and Europe. Tibor Juhasz, PhD, founder and former Chief Executive Officer, has transitioned to the role of President and Chief Technology Officer, where he will continue to guide the company’s technological innovation roadmap. Shawn O’Neil, most recently Chief Commercial Officer, has been appointed Chief Executive Officer. In turn, Pete England has been promoted to Chief Commercial Officer. “These leadership changes mark an important milestone in ViaLase’s evolution,” said Tom Frinzi, Executive Chairman of the Board. “Tibor has done an extraordinary job building a world-class R&D and clinical organization, laying the foundation for what promises to be a major advancement in glaucoma care. His track record as an entrepreneu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom